CONMED (NYSE:CNMD – Get Free Report) is expected to release its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect CONMED to announce earnings of $1.00 per share and revenue of $336.28 million for the quarter. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.
CONMED (NYSE:CNMD – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.11 by $0.27. The business had revenue of $343.49 million for the quarter, compared to the consensus estimate of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%. The company’s revenue was up .3% on a year-over-year basis. During the same period last year, the business posted $1.15 EPS. On average, analysts expect CONMED to post $4.54 EPS for the current fiscal year and $4.73 EPS for the next fiscal year.
CONMED Trading Up 3.3%
CNMD opened at $47.58 on Wednesday. The firm’s 50 day moving average is $47.54 and its 200-day moving average is $41.44. CONMED has a 52-week low of $31.44 and a 52-week high of $53.66. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $1.43 billion, a P/E ratio of 25.72, a P/E/G ratio of 2.10 and a beta of 0.94.
Analysts Set New Price Targets
CNMD has been the subject of several research analyst reports. BMO Capital Markets started coverage on shares of CONMED in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 target price for the company. Wells Fargo & Company lifted their price target on CONMED from $39.00 to $46.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Wall Street Zen raised CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Needham & Company LLC restated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $45.00 target price (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, CONMED presently has an average rating of “Reduce” and an average target price of $41.40.
Read Our Latest Stock Analysis on CONMED
About CONMED
CONMED Corporation (NYSE: CNMD) is a medical technology company that develops, manufactures and markets products used in minimally invasive surgical procedures. Its offerings support healthcare providers across a range of specialties, including general surgery, gastroenterology, pulmonology, gynecology, orthopedics and sports medicine.
The company’s products include advanced surgical devices and systems, electrosurgical equipment, smoke evacuation systems, endoscopic instruments, powered surgical tools, and orthopedic products used in arthroscopic and reconstructive procedures.
Further Reading
- Five stocks we like better than CONMED
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
